JP2020528890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528890A5 JP2020528890A5 JP2020503013A JP2020503013A JP2020528890A5 JP 2020528890 A5 JP2020528890 A5 JP 2020528890A5 JP 2020503013 A JP2020503013 A JP 2020503013A JP 2020503013 A JP2020503013 A JP 2020503013A JP 2020528890 A5 JP2020528890 A5 JP 2020528890A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- modified
- nucleic acid
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 23
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000002299 complementary DNA Substances 0.000 claims 11
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 5
- 101000972324 Cynodon dactylon Leaf protein Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 241000710124 Human rhinovirus A2 Species 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 2
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 claims 2
- 108091023045 Untranslated Region Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 108091023685 miR-133 stem-loop Proteins 0.000 claims 2
- 108091063796 miR-206 stem-loop Proteins 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- -1 anthracyclines Chemical compound 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710600732.8A CN109276580B (zh) | 2017-07-21 | 2017-07-21 | 一种用于治疗肿瘤的病毒 |
| CN201710600732.8 | 2017-07-21 | ||
| PCT/CN2018/096100 WO2019015601A1 (zh) | 2017-07-21 | 2018-07-18 | 一种用于治疗肿瘤的病毒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528890A JP2020528890A (ja) | 2020-10-01 |
| JP2020528890A5 true JP2020528890A5 (enExample) | 2020-11-26 |
| JP7144915B2 JP7144915B2 (ja) | 2022-09-30 |
Family
ID=65015869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503013A Active JP7144915B2 (ja) | 2017-07-21 | 2018-07-18 | 腫瘍を治療するためのウイルス |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11793844B2 (enExample) |
| EP (1) | EP3656854A4 (enExample) |
| JP (1) | JP7144915B2 (enExample) |
| KR (1) | KR102566552B1 (enExample) |
| CN (2) | CN109276580B (enExample) |
| AU (1) | AU2018303064B2 (enExample) |
| WO (1) | WO2019015601A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108424881B (zh) * | 2018-03-23 | 2021-07-27 | 中国食品药品检定研究院 | 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用 |
| CN110283794B (zh) * | 2019-05-30 | 2021-04-23 | 伍泽堂 | 重组溶瘤病毒以及制备方法、应用和药物 |
| TW202242105A (zh) * | 2021-04-17 | 2022-11-01 | 景均股份有限公司 | Vero細胞適應培養之D68型腸病毒、D68型腸病毒疫苗及其用途 |
| CN114561358B (zh) * | 2022-03-09 | 2023-10-03 | 广州源井生物科技有限公司 | 一种提高细胞慢病毒感染率的增强感染培养基及方法 |
| WO2024086609A2 (en) * | 2022-10-19 | 2024-04-25 | Kalivir Immunotherapeutics, Inc. | Nucleic acids encoding soluble pd-1 and il-12 and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2559055A1 (en) * | 2004-03-11 | 2005-09-22 | Virotarg Pty Ltd. | Modified oncolytic viruses |
| CN101065144B (zh) * | 2004-08-20 | 2012-06-13 | 溶瘤病毒有限公司 | 治疗血液癌症的方法和组合物 |
| WO2008103755A1 (en) | 2007-02-20 | 2008-08-28 | Mayo Foundation For Medical Education And Research | Treating cancer with viral nucleic acid |
| JP2016500108A (ja) | 2012-11-21 | 2016-01-07 | デューク ユニバーシティー | ヒトの腫瘍のための腫瘍溶解性ポリオウイルス |
| EP2987858B1 (en) | 2013-04-17 | 2019-08-14 | Kyushu University, National University Corporation | Gene-modified coxsackievirus |
| WO2014170389A1 (en) | 2013-04-18 | 2014-10-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| EP2826856B9 (en) * | 2013-07-16 | 2016-05-04 | Sia Latima | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof |
| CN106029889A (zh) * | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| WO2016044656A1 (en) | 2014-09-17 | 2016-03-24 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus d68 |
| US10752966B2 (en) * | 2015-04-24 | 2020-08-25 | Washington University | Methods and compositions for detection of enterovirus D68 |
| US9938588B2 (en) * | 2015-06-05 | 2018-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for detecting Enterovirus D68 |
-
2017
- 2017-07-21 CN CN201710600732.8A patent/CN109276580B/zh active Active
-
2018
- 2018-07-18 US US16/632,741 patent/US11793844B2/en active Active
- 2018-07-18 EP EP18835927.7A patent/EP3656854A4/en active Pending
- 2018-07-18 AU AU2018303064A patent/AU2018303064B2/en active Active
- 2018-07-18 KR KR1020207005067A patent/KR102566552B1/ko active Active
- 2018-07-18 CN CN201880048812.XA patent/CN110996980B/zh active Active
- 2018-07-18 JP JP2020503013A patent/JP7144915B2/ja active Active
- 2018-07-18 WO PCT/CN2018/096100 patent/WO2019015601A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528890A5 (enExample) | ||
| JP6419706B2 (ja) | ミニプロモーターカセットを含むレトロウイルスベクター | |
| Callegari et al. | Anti-tumor activity of a miR-199-dependent oncolytic adenovirus | |
| JP2020524993A5 (enExample) | ||
| JP2008545406A5 (enExample) | ||
| Yi et al. | Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models | |
| JP2021514190A (ja) | コード化リボ核酸の器官保護発現および調節のための組成物および方法 | |
| TWI545196B (zh) | Ｒｅｉｃ表現腺病毒載體 | |
| JPWO2019093435A1 (ja) | 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療） | |
| JP2023159160A (ja) | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス | |
| JP2007508036A (ja) | 肝細胞癌特異的プロモーターおよびその使用 | |
| Qu et al. | Inhibitory effect of biosynthetic nanoscale peptide Melittin on hepatocellular carcinoma, driven by survivin promoter | |
| CN110387353B (zh) | 一种用于治疗肿瘤的柯萨奇b组病毒 | |
| JP2020537534A5 (enExample) | ||
| JP6803619B2 (ja) | ＲＥＩＣ／Ｄｋｋ−３遺伝子およびチェックポイント阻害剤を用いた併用療法 | |
| US20240076689A1 (en) | Viral vectors and nucleic acids for regulated gene therapy | |
| JP2025141963A (ja) | ウイルスを含む抗癌関連非腫瘍細胞剤 | |
| JPWO2019201192A5 (enExample) | ||
| CA2675342C (en) | A method for diagnosing disease using adenovirus harboring trans-splicing ribozyme by molecular imaging | |
| JP7699122B2 (ja) | 複製促進腫瘍溶解性アデノウイルス | |
| RU2551784C1 (ru) | Универсальный промотор для экспрессии терапевтических генов в клетках млекопитающих | |
| JP5713306B2 (ja) | ガンのリンパ節転移抑制剤 | |
| RU2020100074A (ru) | Композиции, содержащие куроны, и пути их применения | |
| WO2013189287A1 (zh) | 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法 | |
| HK40022397B (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue |